Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK139 in Moderate to Severe Atopic Dermatitis
NCT07502222Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of AK139 in atopic dermatitis (AD), sponsored by Akeso, Inc.. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
AK139
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07502222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502222.